Stock Groups

BioNTech, Pfizer say test shows 3 doses of vaccine neutralise Omicron -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – This illustration shot taken March 19, 2021, shows an illustrated vial that has been labelled with Pfizer BioNTech coronavirus virus disease (COVID-19). REUTERS/Dado Ruvic

(Reuters) – BioNTech Pfizer (NYSE) announced Wednesday that in laboratory testing, a three-shot COVID-19 shot was able to neutralize the Omicron variant.

BioNTech, Pfizer and others made the initial official statements from the vaccine makers regarding the efficacy of the shot against Omicron. They stated that although two doses of vaccine resulted significantly in lower levels of neutralising antibodies, a third dose increased neutralising antibody by 25.

They also stated that they could deliver an Omicron vaccine in March 2022 if necessary.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]